Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Antitubercular Agents Clear all
Completed Not applicable Interventional

A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients

NCT00000947
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
19
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jul 21, 2026, 9:21 PM EDT
Terminated No phase listed Observational

Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali

NCT01381757
View directory record Official record
Conditions
Tuberculosis, Pulmonary, Mycobacterium Tuberculous, Antitubercular Agents, Tuberculosis, Mulutidrug-Resistant, Extensively Drug-Resistant, Extensibely Drug-Resistant Tuberculosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jul 21, 2026, 9:21 PM EDT
Terminated Phase 3 Interventional

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

NCT06418711
View directory record Official record
Conditions
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
Interventions
Clofazimine Inhalation Suspension, Placebo
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
54
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 21, 2026, 9:21 PM EDT
Completed Not applicable Interventional

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

NCT00002032
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Rifabutin
Drug
Lead sponsor
Pharmacia
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
33
States / cities
Irvine, California • Sylmar, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 9:21 PM EDT
Completed Not applicable Interventional

Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection

NCT00000959
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Isoniazid, Pyridoxine hydrochloride
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 21, 2026, 9:21 PM EDT
Completed Phase 1 Interventional

Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis

NCT00004736
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Nelfinavir mesylate, Ethambutol hydrochloride, Isoniazid, Pyrazinamide, Lamivudine, Rifabutin, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2008 · Synced Jul 21, 2026, 9:21 PM EDT
Withdrawn Phase 4 Interventional

Once Weekly D-cycloserine for Schizophrenia

NCT00964041
View directory record Official record
Conditions
Schizophrenia
Interventions
D-cycloserine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Jul 21, 2026, 9:21 PM EDT
Completed Phase 2 Interventional

Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.

NCT00002192
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Rifapentine, Ethambutol hydrochloride, Clarithromycin, Azithromycin
Drug
Lead sponsor
Anderson Clinical Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Hampton, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 9:21 PM EDT
Completed Not applicable Interventional

Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection

NCT00000638
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Rifampin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
75
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Jul 21, 2026, 9:21 PM EDT
Completed Not applicable Interventional

Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis

NCT00000950
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Ethambutol hydrochloride, Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Rifampin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Los Angeles, California • Torrance, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Jul 21, 2026, 9:21 PM EDT
Completed Not applicable Interventional

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

NCT00002267
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Rifabutin
Drug
Lead sponsor
Pharmacia
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
31
States / cities
Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 9:21 PM EDT
Completed Not applicable Interventional

Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection

NCT00000636
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Rifampin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
25
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Jul 21, 2026, 9:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults

NCT00096850
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Atazanavir, Rifampin, Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2007
U.S. locations
3
States / cities
Palo Alto, California • Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 21, 2026, 9:21 PM EDT
Completed Not applicable Interventional Results available

D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia

NCT00963924
View directory record Official record
Conditions
Schizophrenia
Interventions
D-cycloserine, Placebo, Cognitive Remediation
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Jul 21, 2026, 9:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers

NCT01162486
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
Rifampin & midazolam, rifapentine and midazolam
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Jul 21, 2026, 9:21 PM EDT
Completed Phase 2 Interventional Results available

A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)

NCT00685360
View directory record Official record
Conditions
Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant, Extensively Drug-Resistant Tuberculosis
Interventions
Delamanid, Optimized Background Regimen (OBR), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Jul 21, 2026, 9:21 PM EDT